TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16970537
Drug: Gargling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gargling with tea catechin extract solution (200 microg/mL catechins, 60% epigallocatechin gallate), performed three times daily for 3 months.
Study: 16970537
Drug: Gargling without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gargling without tea catechin extracts (control group), performed three times daily for 3 months.
Study: 26552175
Drug: OMT low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT low dose (1.89 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Study: 26552175
Drug: OMT medium
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT medium dose (3.78 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Study: 26552175
Drug: OMT high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT high dose (7.56 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Study: 26552175
Drug: SB203580 (p38MAPK
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB203580 (p38MAPK blocking agent, 1 x 10(‐5) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Study: 26552175
Drug: Model group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model group (20 μg x L(‐1) TGF‐β1)
Study: 22042952
Drug: 3 or
Normalized name: Cytra-3 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 or 4 months of androgen suppression therapy (AST)
Study: 10905240
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (omeprazole 20 mg, clarithromycin 250 mg, and tinidazole 500 mg, each twice daily for 7 days)
Study: 8730248
Drug: roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 150 mg at 07.30 h (early evening)
Study: 8730248
Drug: roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 150 mg at 22.00 h (bedtime)
Study: 1417177
Drug: r‐hGH (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐hGH (0.1 mg/kg/day or 0.2 mg/kg/day) + insulin (1 mU/kg/minute)
Study: 1417177
Drug: insulin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin (1 mU/kg/minute)
Study: 31923070
Drug: Opioid use
Normalized name: Modia Opioid Use Disorder Support Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid use disorder treatment
Study: 25786714
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol 0.05% applied at night
Study: 25786714
Drug: Systemic mycophenolate
Normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic mycophenolate mofetil (MMF) 2 g/day
Study: 20472399
Drug: LPD 7/7
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPD 7/7 (low protein diet providing 0.8 g/kg per day, 7 days a week)
Study: 20472399
Drug: LPD 6/7
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPD 6/7 (low protein diet providing 0.8 g/kg per day, 6 days a week)
Study: 15231567
Drug: Brief anthracycline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief anthracycline-based chemotherapy plus high-dose extended irradiation
Study: 11300386
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, bolus of 0.05 ml/kg, lockout interval of 10 min, total dose limit of three bolus doses per hour.
Study: 11300386
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (EPI) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, continuous infusion of 0.1 ml kg(‐1) h(‐1) and a minimal extra bolus dose of 0.2 ml with the same lockout interval.
Study: 9129064
Drug: zalcitabine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: zalcitabine (0.03 mg/kg/day) in combination with zidovudine (720 mg/m2/day)
Study: 3203716
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg oral dose in the fasted state
Study: 3203716
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg oral dose with a standard breakfast
Study: 3203716
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg oral dose in the fed state
Study: 3203716
Drug: Cefixime 400
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 400 mg oral dose in both states
Study: 31743987
Drug: Corticosteroid (COR)
Normalized name: Aspi-Cor
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid (COR) injection
Study: 31743987
Drug: Prolotherapy (PRO)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolotherapy (PRO) injection
Study: 21254641
Drug: Standard antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibacterial treatment plus immunotropic drug (lavomax) 1.25 g
Study: 21254641
Drug: Standard antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibacterial treatment
Study: 12639206
Drug: Dehydroepiandrosterone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dehydroepiandrosterone (50 mg/d)
Study: 11095459
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (fenfluramine, 60 mg/day) coupled with an energy-restricted diet (−2930 kJ/day)
Study: 11095459
Drug: High-insulin individuals
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-insulin individuals
Study: 29490294
Drug: Furosemide (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (60-120 mg/day, intravenously) for 1 week
Study: 29490294
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no furosemide or other diuretics)
Study: 25268730
Drug: Rhodiola rosea
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea (364 mg daily for 42 days)
Study: 25268730
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical capsule daily for 42 days)
Study: 22977989
Drug: Spray product
Normalized name: Oral Spray Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray product
Study: 18689370
Drug: Bread fortified
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread fortified with 138 µg folic acid and 9.6 µg vitamin B-12 daily
Study: 16199244
Drug: Muraglitazar 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muraglitazar 2.5 mg
Study: 16199244
Drug: Muraglitazar 5
Normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muraglitazar 5 mg
Study: 16199244
Drug: Muraglitazar 5
Normalized name: Muraglitazar
DrugBank: Muraglitazar (DB06510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muraglitazar 5 mg (open-label cohort)
Study: 10586004
Drug: Td vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Td vaccine with pa vaccine
Study: 10586004
Drug: dTpa and
Approvals — FDA: no, EMA: no, PMDA: no
Description: dTpa and pa vaccines
Study: 8915665
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized progesterone (300 mg/day, at bedtime)
Study: 8915665
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone (300 mg/day)
Study: 1888621
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel (1 g diclofenac/100 g, 80 mg three times daily)
Study: 1888621
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel and Placebo gel
Study: 3936085
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg dextroamphetamine sulfate
Study: 28599060
Drug: Sacubitril/valsartan 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 400 mg once daily for 5 days
Study: 22676908
Drug: Endoscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic surgery for hematoma evacuation and the best medical treatment
Study: 22676908
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (the best medical treatment)
Study: 15830639
Drug: SRP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP and 14% doxycycline gel (DOX)
Study: 15830639
Drug: SRP with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP with subgingival placebo gel (VEH)
Study: 11852170
Drug: Inactivated Influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated Influenza Vaccine
Study: 2910293
Drug: Retrobulbar injections
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retrobulbar injections (5 mL)
Study: 2910293
Drug: Periocular injections
Normalized name: autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand
DrugBank: RR001 (DB17369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injections (5 mL)
Study: 28873284
Drug: Ultrasound-guided PRP
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided PRP injection
Study: 28749177
Drug: Systolic blood
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systolic blood pressure treatment target of 120 mmHg
Study: 28749177
Drug: Systolic blood
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systolic blood pressure treatment target of 120 mmHg in the lowest tertile of baseline systolic blood pressure
Study: 28749177
Drug: Systolic blood
Normalized name: Bystolic
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systolic blood pressure treatment target of 140 mmHg
Study: 21435016
Drug: Cresco components
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cresco components loaded 10 days post-implant placement
Study: 21435016
Drug: Cresco components
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cresco components loaded 6-8 weeks post-implant placement
Study: 21435016
Drug: Conventional components
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional components loaded 6-8 weeks post-implant placement
Study: 10919344
Drug: Flucozole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flucozole (200 mg)
Study: 10919344
Drug: Diflucan (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflucan (200 mg)
Study: 3880556
Drug: Prednisone (10-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10-15 mg daily)
Study: 24394343
Drug: TRPV1 antagonist
Normalized name: Tetrahydronaphthyl urea based selective TRPV1 antagonist
DrugBank: XEN-D0501 (DB18673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRPV1 antagonist AZD1386
Study: 20881647
Drug: Enzastaurin 500
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzastaurin 500 mg orally daily (after a loading dose) plus pemetrexed 500 mg/m², carboplatin AUC 6, and bevacizumab 15 mg/kg intravenously every 21 days for four cycles.
Study: 20881647
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus pemetrexed 500 mg/m², carboplatin AUC 6, and bevacizumab 15 mg/kg intravenously every 21 days for four cycles.
Study: 18590751
Drug: Oral mucosal
Normalized name: Finafta Multi Oral Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mucosal wetness
Study: 2169078
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin) at a dose of 75 U/kg/day for 5 days (I group, n = 27)
Study: 2169078
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin) at a dose of 150 U/kg/day for 5 days (II group, n = 29)
Study: 75391
Drug: Dextropropoxyphene/paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene/paracetamol
Study: 28017166
Drug: Interlaminar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interlaminar epidural steroid injections
Study: 24495046
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) for 5 days and rectal enema
Study: 22784287
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (RS)
Study: 19960971
Drug: Yangyin Jiedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yangyin Jiedu Huoxue Recipe (YJHR) plus conventional Western medical treatment
Study: 19960971
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medical treatment only (Control)
Study: 17613964
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg per day
Study: 12118271
Drug: Hypertonic/hyperoncotic solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic/hyperoncotic solution
Study: 3305681
Drug: 15 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/die methimazole (group A)
Study: 3305681
Drug: 30 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/die methimazole (group B)
Study: 27733248
Drug: Lower fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower fat diet vs. lower carbohydrate diet (insulin sensitive women)
Study: 27733248
Drug: Walnut-rich diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut-rich diet vs. lower carbohydrate diet (insulin sensitive women)
Study: 27733248
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (Sex hormone binding globulin)
Study: 20171784
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day oral raloxifene hydrochloride
Study: 20171784
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day oral raloxifene hydrochloride
Study: 14694042
Drug: Gabapentin (GPT)
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin (GPT) 2,400 mg/day
Study: 11068976
Drug: Extended 14‐session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended 14‐session cognitive‐behavioral group treatment (RPSG)
Study: 11068976
Drug: Brief 2‐session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief 2‐session individual treatment using motivational interviewing (IAI)
Study: 11068976
Drug: 4‐month delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐month delayed treatment control (DTC)
Study: 8631163
Drug: 3000 IU
Normalized name: Cholecalciferol 3000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 IU bolus of heparin
Study: 8631163
Drug: 5000 IU
Normalized name: D 5000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5000 IU bolus of heparin
Study: 1531927
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 6 weeks
Study: 11209118
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 12 weeks
Study: 1531927
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg/day for 24 weeks
Study: 25878124
Drug: Nanoparticles (NPs)
Normalized name: Doxorubicin nanoparticles
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanoparticles (NPs) targeted to inflammatory vascular molecules (VCAM‐1, E‐selectin, ICAM‐1).
Study: 21562990
Drug: Polypharmacy (using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (using more than four medications)
Study: 21562990
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication review at baseline
Study: 16849762
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg bid with dexamethasone 4 mg daily
Study: 16849762
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg bid with placebo
Study: 15327614
Drug: Metronidazole (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1000 mg oral before abortion followed by 500 mg twice daily)
Study: 9317068
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and metronidazole 500 mg b.i.d. (LCM) for 7 days
Study: 9317068
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d., clarithromycin 500 mg b.i.d., and bismuth subsalicylate 524 mg b.i.d. (LCB) for 7 days
Study: 8403910
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to pregnant women
Study: 8403910
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (25, 100, 400, and 600 mg); single oral doses administered to non-pregnant women
Study: 8403910
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (200 mg); additional dose for 6 non-pregnant women
Study: 18510549
Drug: L-arginine (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (18 g daily for 6 months)
Study: 18510549
Drug: Control (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (18 g dextrose daily for 6 months)
Study: 8770627
Drug: Slightly suppressive
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slightly suppressive L-thyroxine doses (50-200 micrograms/day)
Study: 6117459
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg clotiazepam
Study: 31600034
Drug: Oral nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonsteroidal antiinflammatory therapy
Study: 22299715
Drug: Bismuthyl ecabet
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuthyl ecabet 400 mg single dose
Study: 22299715
Drug: Bismuthyl ecabet
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuthyl ecabet 800 mg single dose
Study: 22299715
Drug: Bismuthyl ecabet
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuthyl ecabet 1200 mg single dose
Study: 22299715
Drug: Bismuthyl ecabet
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuthyl ecabet 200 mg single dose
Study: 22299715
Drug: Bismuthyl ecabet
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuthyl ecabet 1600 mg single dose
Study: 22299715
Drug: Bismuthyl ecabet
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuthyl ecabet 1200 mg twice daily (multiple dose)
Study: 11994358
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg ciclesonide inhaled twice daily
Study: 21157021
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg bid)
Study: 22716774
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU: n = 32)
Study: 17013635
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules containing lactose
Study: 30084152
Drug: Moisturizing gel
Normalized name: MOISTURIZING GEL
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moisturizing gel containing a pseudo‐ceramide and a eucalyptus extract, applied twice a day for 4 weeks.
Study: 29053121
Drug: Cavinton R
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton R for drop infusions (10 intravenously during 10 days) followed by cavinton R comforte in dose 10 mg, 1 tablet 3 times a day during 90 days
Study: 29053121
Drug: Cavinton R
Normalized name: R-348
DrugBank: R-348 (DB06321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavinton R for drop infusions and cavinton R comforte
Study: 21958025
Drug: 2 μg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg·kg(‐1) fentanyl (group F, n = 40)
Study: 21958025
Drug: 2 mg·kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg·kg(‐1) tramadol (group T, n = 40)
Study: 9679573
Drug: Function-preserving operations
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Function-preserving operations (e.g., EMR)
Study: 1703598
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg intravenous isradipine
Study: 1703598
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravenous nifedipine
Study: 28680540
Drug: Somatic Experiencing
Normalized name: Bos taurus somatic nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatic Experiencing (SE) in addition to treatment-as-usual (TAU)
Study: 22247720
Drug: EPA +
Normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPA + vitamin C (500 mg EPA and 200 mg vitamin C)
Study: 22247720
Drug: EPA +
Normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPA + placebo (500 mg EPA and placebo vitamin C)
Study: 22247720
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + vitamin C (placebo EPA and 200 mg vitamin C)
Study: 19535716
Drug: Ropivacaine infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infiltration (20 mL of ropivacaine 0.75%)